BMAL2 and pancreatic ductal adenocarcinoma: Zhifang Wang et.al found that miR-26a-5p suppressed the pancreatic ductal adenocarcinoma (PDAC) progression by targeting ARNTL2, which means that ARNTl2 acted as an oncogene to regulate PDAC growth [67].